Publications by authors named "Serena Giolitto"

Claim this Profile
S
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
Domenica Lorusso, Francesco Raspagliesi, Dominique Ronzulli, Giorgio Valabrega, Nicoletta Colombo, Serena Giolitto

J Clin Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
Domenica Lorusso, Sandro Pignata, Stefano Tamberi, Giorgia Mangili, Alessandra Bologna, Serena Giolitto

Gynecol Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
Lucia Musacchio, Vanda Salutari, Sandro Pignata, Elena Braicu, David Cibula, Serena Giolitto

Int J Gynecol Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Coup-TFII orphan nuclear receptor is an activator of the γ-globin gene.
Cristina Fugazza, Gloria Barbarani, Sudharshan Elangovan, Maria Giuseppina Marini, Serena Giolitto

Haematologica· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Domenica Lorusso, Giuseppa Maltese, Ilaria Sabatucci, Sara Cresta, Cristina Matteo, Serena Giolitto

Target Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis